key: cord-1023108-2kfitfhx
authors: Mungmunpuntipantip, Rujittika; Wiwanitkit, Viroj
title: SARS CoV-2 vaccine AND rituximab. Comment on: “SARS CoV-2 vaccine AND rituximab, timing is probably a key for a better vaccine response” by Verhoeven Joint Bone Spine. 2021;88:105258
date: 2021-09-29
journal: Joint Bone Spine
DOI: 10.1016/j.jbspin.2021.105281
sha: c5e01d7d038987759ffa58b6db26c3af0b14d223
doc_id: 1023108
cord_uid: 2kfitfhx

nan

Journal Pre-proof SARS CoV-2 vaccine AND rituximab. Comment on: "SARS CoV-2 vaccine AND rituximab, timing is probably a key for a better vaccine response" by Verhoeven We would like to share ideas on "SARS CoV-2 vaccine AND rituximab, timing is probably a key for a better vaccine response [1] " Interrelationship between SARS CoV-2 vaccine AND rituximab is an interesting issue. For COVID-19, rituximab might induce sever outcome [2] . The similar process might be expected for COVID-19 vaccination. Timing might be important but it is largely unknown for "what is the best period for vaccination?" Based on present available data, at least 3week period waiting after receiving rituximab is proven useful for improving immune response after COVID-19 vaccination [3] . Nevertheless, a recent report showed that rituximab did not preclude 2 vaccination since effective cellular immunity stimulation still exists [4] .

SARS CoV-2 vaccine AND rituximab, timing is probably a key for a better vaccine response

Protracted severe COVID-19 pneumonia following rituximab treatment: caution needed

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma

Presence of specific T cell response after SARS-CoV-2 vaccination in rheumatoid arthritis patients receiving rituximab